樂觀
$2.22
情境價格
$1.495
+0.125 (+8.33%)收盤時
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Spectral AI to Report Q3 Financial Results on November 10, 2026

Spectral AI Showcases DeepView System at ACEP Conference

Spectral AI Unveils DeepView System for Burn Assessment

Spectral AI to Report Q2 Financial Results on August 11, 2026

Spectral AI Appoints New Chief Commercial Officer
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。